Harmony Gold Mining Co. vs Vaxcyte Inc. Common Stock — how do they compare? Harmony Gold Mining Co. trades at $16.47 (market cap $10.37B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Harmony Gold Mining Co. and Vaxcyte Inc. Common Stock are close in size by market cap, and Harmony Gold Mining Co. pays a 4.67% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Harmony Gold Mining Co. for 45 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| HMY | PCVX | |
|---|---|---|
Market Cap | $10.37B | $10.51B |
Volume | 2,951,252 | 2,644,694 |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $73.82 |
52-Week Low | $13.32 | $40.32 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $10.42B | $9.14B |
Dividend Yield | 4.67% | — |
Signals from Pluang's Aura AI — not financial advice
HMY trades at $16.29, down 2.34% today, amid bearish technical signals but strong fundamentals. The stock shows robust revenue growth from $42.6B in 2022 to $73.9B in 2025, with net income surging to $14.4B. Valuation ratios remain attractive with P/E of 5.96 and EV/EBITDA of 3.64. Recent earnings showed mixed results with two beats and two misses in the last four quarters.
The outlook is cautiously optimistic given strong profitability metrics (ROE 46.23%, net margin 29.57%) and copper expansion plans, though technical weakness and analyst skepticism (70% hold rating) suggest near-term volatility. Key risks include gold price dependency and execution challenges in diversification efforts.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →